Want to track EW and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 52 days
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
Edwards Lifesciences' (EW) TMTT segment's PASCAL platform is likely to have maintained strong growth momentum in the second quarter globally, backed by its portfolio of differentiated therapies.
Zacks | 1 year ago
Here's Why You Should Retain Edward Lifesciences (EW) for Now
Investors are optimistic about Edward Lifesciences (EW), led by the strong performance of its SAPIEN 3 Ultra RESILIA platform and strong solvency.
Zacks | 1 year ago
2025 © Marketlog. All Rights Reserved.
